OncoSil Medical (ASX: OSL) shares have climbed another 9.9% intra-day to $0.089 today, with the upward momentum in the stock continuing to gather speed. Around a month ago OncoSil was trading at $0.029.
At the start of July the company appointed Dr Neil Frazer as chief executive officer to drive the next stage of development and potential approval of OncoSil™ device for pancreatic cancer treatment.
Frazer will be taking the leadership position on driving the development of the OncoSil™ device with the global regulatory authorities, with the FDA and EMA approval for pancreatic cancer the core focus of OncoSil™.
Frazer has a background in drug development in multiple therapeutic areas which includes oncology drug development, and has been responsible for successful U.S. Food and Drug Administration applications for ten new chemical entities and over twenty applications for the line extensions of pharmaceutical drug applications.
OncoSil™ is a bio-silica P32(phosphorous) pure beta emitter with the potential to be used medically as a brachytherapy treatment.
The OncoSil™ device delivers more concentrated and localised beta radiation compared to external beam radiation, with potential for the device in other solid tumors outside of pancreatic cancer.
Proactive Investors Australia is the market leader in producing news, articles and research reports on ASX “Small and Mid-cap” stocks with distribution in Australia, UK, North America and Hong Kong / China.